Controlling the complement system in inflammation

Immunopharmacology

Volumn 38, Issue 1-2, 1997, Pages 51-62

  Kirschfink, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antibodies; Complement inhibition; Complement regulators; Inflammation; Therapy

Indexed keywords

ANAPHYLATOXIN; ANTIBODY; CD11B ANTIGEN; CD18 ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; GENETIC TRANSFECTION; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; INFLAMMATION; INTESTINE ISCHEMIA; MULTIPLE ORGAN FAILURE; NEPHRITIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK; TISSUE INJURY;

ANAPHYLATOXINS; ANIMALS; CLINICAL TRIALS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; GRAFT REJECTION; HUMANS; INFLAMMATION; MULTIPLE ORGAN FAILURE; RECEPTORS, COMPLEMENT; SHOCK, SEPTIC;

EID: 0031473586     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(97)00057-X     Document Type: Review

References (118)

1. Ames, R.S., Tornetta, M.A., Jones, C.S., Tsui, P., 1994. Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent Fab display library. J. Immunol. 152, 4572-4581.
2. Araida, T., Frey, C.F., Ruebner, B., Carlson, J., King, J., 1995. Therapeutic regimens in acute experimental pancreatitis in rats: Effects of a protease inhibitor, a beta-agonist, and antibiotics. Pancreas 11, 132-140.
3. Asghar, S.S., 1984. Pharmacological manipulation of complement system. Pharm. Rev. 36, 223-244.
4. Azimzadeh, A., Wolf, P., Dalmasso, A.P., Odeh, M., Beller, J.P., Fabre, M., Charreau, B., Thibaudeau, K., Cinqualbre, J., Soulillou, J.P., Anegon, I., 1996. Assessment of hyperacute rejection in a rat-to-primate cardiac xenograft model. Transplantation 61, 1305-1313.
5. Basta, M., Dalakas, M.C., 1994. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermato-myositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729-1735.
6. Basta, M., Kirschbom, P., Frank, MM., Fries, L.F., 1989. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute complement-dependent immune damage in a guinea pig model. J. Clin. Invest. 84, 1974-1981.
7. Bork, K., Witzke, G., 1988. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J. Allergy Clin. Immunol. 63, 677-682.
8. Buerke, M., Murohara, T., Lefer, A.M., 1995. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91, 393-402.
9. Byrne, G.W., McCurry, K.R., Martin, M.J., Platt, J.L., Logan, J.S., 1996. Development and analysis of transgenic pigs expressing the human complement regulatory protein CD59 and DAF. Transplant. Proc. 28, 759.
10. Byrne, G.W., McCurry, K.R., Martin, M.J., McClellan, S.M., Platt, J.L., Logan, J.S., 1997. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 63, 149-155.
11. Carrell, R.W., Boswell, D.R., 1986. Serpins: The superfamily of plasma serine protease inhibitors. In: Barret, A.J., Salvese, G. (Eds.), Proteinase Inhibitors. Elsevier, Amsterdam, pp. 403-420.
12. Carroll, M.C., Fischer, M.B., 1997. Complement and the immune response. Curr. Opin. Immunol. 9, 64-69.
13. Chavez Cartaya, R.E., DeSola, G.P., Wright, L., Jamieson, N.V., White, D.J., 1995. Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. Transplantation 59, 1047-1052.
14. Chenoweth, D.E., 1986. Anaphylatoxin formation in extracorporeal circuits. Complement 3, 152-165.
15. Cheung, A.K., 1994. Complement activation as index of hemodialysis membrane biocompatibility: The choice of methods and assays. Nephrol. Dial. Transplant. 9, 96-103.
16. Cheung, A.K., Parker, C.J., Janatova, J., Brynda, E., 1992. Modulation of complement activation on hemodialysis membranes by immobilized heparin. J. Am. Soc. Nephrol. 2, 1328-1337.
17. Chrupcala, M., Pomer, S., Staehler, G., Waldherr, R., Kirschfink, M., 1994. Prolongation of discordant renal xenograft survival by depletion of complement. Comparative effects of systemically administered cobra venom factor and soluble complement receptor type 1 in a guinea pig-to-rat model. Transplant. Int. 7, 650-653.
18. Cochrane, C.G., Müller-Eberhard, H.J., Aikin, B.S., 1970. Depletion of plasma complement in vivo by a protein of cobra venom: Its effect on various immunologic reactions. J. Immunol. 105, 55-69.
19. Cooper, N.R., Nemerow, G.R., Mayes, J.T., 1983. Methods to detect and quantitate complement activation. Springer Semin. Immunopathol. 6, 195-212.
20. Couser, W.G., Johnson, R.J., Young, B.A., Yeh, C.G., Toth, C.A., Rudolph, A.R., 1995. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J. Am. Soc. Nephrol. 5, 1888-1894.
21. Cozzi, E., White, D.J., 1995. The generation of transgenic pigs as potential organ donors for humans. Nat. Med. 1, 964-966.
22. Crepon, B., Maillet, F., Kazatchkine, M.D., Jozefonvicz, J., 1987. Molecular weight dependency of the acquired anti-complementary and anticoagulant activities of specifically substituted dextrans. Biomaterials 8, 248-253.
23. Dalmasso, A.P., 1986. Complement in the pathophysiology and diagnosis of human diseases. Crit. Rev. Clin. Lab. Sci. 24, 123-183.
24. Dalmasso, A.P., 1992. The complement system in xenotransplantation. Immunopharmacology 24, 149-160.
25. Dalmasso, A.P., Vercellotti, G.M., Platt, J.L., Bach, F.H., 1991. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Transplantation 52, 530-533.
26. Dehring, D.J., Steinberg, S.M., Wismar, B.L., Lowery, B.D., Carey, L.C., Cloutier, C.T., 1987. Complement depletion in a porcine model of septic acute respiratory disease. J. Trauma 27, 615-625.
27. Devine, D.V., 1991. The regulation of complement on cell surfaces. Transfusion Med. Rev. V, 123-131.
28. Edens, E.R., Linhardt, R.J., Weiler, J.M., 1993. Heparin is not just an anticoagulant anymore: Six and one-half decades of studies on the ability of heparin to regulate complement activity. In: Cruse, J.N., Lewis, R.E., Jr. (Eds.), Complement Today. Karger, Basel, pp. 96-120.
29. Evans, M.J., Rollins, S.A., Wolff, D.W., Rother, R.P., Norin, A.J., Therrien, D.M. et al., 1995. In vitro and in vivo inhibition of complement activity by a single chain Fv fragment recognizing human C5. Mol. Immunol. 32, 1183-1195.
30. Fearon, D.T., 1979. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membranes. Proc. Natl. Acad. Sci. USA 76, 5867-5871.
31. Fearon, D.T., 1991. Anti-inflammmatory and immunosuppressive effects of recombinant soluble complement receptors. Clin. Exp. Immunol. 86, 43-46.
32. Fritzinger, D.C., Bredehorst, R., Vogel, C.W., 1994. Molecular cloning and derived primary structure of cobra venom factor. Proc. Natl. Acad. Sci. USA 91, 12775-12779.
33. Fujita, Y., Inoue, I., Inagi, R., Miyata, T., Shinzato, T., Sugiyama, S., Miyama, A., Maeda, K., 1993. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia. Nippon Jinzo Gakkai Shi 35, 393-397.
34. Gadek, J.E., Hasea, S.W., Gelfand, J.A., Santaella, M., Wickerhauser, M., Triantaphyllopoulos, D.C., Frank, M.M., 1980. Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N. Engl. J. Med. 302, 542-546.
35. Gardinali, M., Cicardi, M., Agostoni, A., Hugli, T.E., 1986. Complement activation in extracorporeal circulation: Physiological and pathological implications. Pathol. Immunopathol. Res. 5, 352-370.
36. Gewurz, H., Clark, D.S., Cooper, M.D., Varco, R., Good, R.A., 1967. Effect of cobra venom-factor induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation 5, 1296-1303.
37. Gillinov, A.M., Devaleria, P.A., Winkelstein, J.A., Wilson, I., Curtis, W.E., Shaw, D. et al., 1993. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann. Thorac. Surg. 55, 619-624.
38. Gross, W.L., 1994. New developments in the treatment of systemic vasculitis. Curr. Opin. Rheumatol. 6, 11-19.
39. Guerrero, R., Velasco, F., Rodriguez, M., Lopez, A., Rojas, R., Alvarez, M.A., Villalba, R., Rubio, V., Torres, A., del Castillo, D., 1993. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J. Clin. Invest. 91, 2754-2760.
40. Hack, C.E., Ogilvies, A.C., Eisele, B., Eerenberg, A.J.M., Wagstaff, J., Thijs, L.G., 1993. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. 19, 19-28.
41. Harlan, J., 1993. Leukocyte adhesion deficiency syndrome: Insights into the molecular basis of leukocyte emigration. Clin. Immunol. Immunopathol. 67, 16-24.
42. Hartmann, H., Lübbers, B., Casaretto, M., Bautsch, W., Klos, A., Köhl, J., 1993. Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedure. J. Immunol. Methods 166, 35-44.
43. Hecke, F., Schmidt, U., Kola, A., Bautsch, W., Klos, A., Köhl, J., 1997. Analysis of complement proteins in polytrauma patients-correlation with injury severity, sepsis, and outcome. Shock 7, 74.
44. Heckl-Östreicher, B., Wosnik, A., Kirschfink, M., 1996. Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor and soluble complement receptor 1: Analysis in a pig-to-human in vitro model relevant to hyperacute rejection. Transplantation 62, 1-3.
45. Hill, J., Lindsay, T.F., Ortiz, F., Yeh, C.G., Hechtman, H.B., Moore, F.D. Jr., 1992. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 149, 1723-1728.
46. Homeister, J.W., Lucchesi, B.R., 1994. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu. Rev. Pharmacol. Toxicol. 34, 17-40.
47. Höpken, U., Mohr, M., Struber, A., Montz, H., Burchardi, H., Götze, O., Oppermann, M., 1996. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur. J. Immunol. 26, 1103-1109.
48. Hsueh, W., Sun, X., Rioja, L.N., Gonzalez-Crussi, F., 1990. The role of the complement system in shock and tissue injury induced by tumor necrosis factor and endotoxin. Immunology 70, 309-314.
49. Hugli, T.E., 1986. Biochemistry and biology of anaphylatoxins. Complement 3, 111-127.
50. Huitinga, I., Damoiseaux, J.G.M.C., Döpp, E.A., Dijkstra, C.D., 1993. Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats. Eur. J. Immunol. 23, 709-715.
51. Inagi, R., Miyata, T., Maeda, K., Sugiyama, S., Miyama, A., Nakashima, I., 1991. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol. Lett. 27, 49-52.
52. Jaeschke, H., Farhood, A., Bautista, A.P., Spolarics, Z., Spitzer, J.J., 1993. Complement activates Kuffer cells and neutrophils during reperfusion after hepatic ischemia. Am. J. Physiol. 264, 801-809.
53. Janatova, J., Cheung, A., Parker, C.J., 1991. Biomedical polymers differ in their capacity to activate complement. Complement Inflamm. 8, 61-69.
54. Johnson, R.J., 1994. Complement activation during extracorporeal therapy: Biochemistry, cell biology and clinical relevance. Nephrol. Dial. Transplant. 9, 36-45.
55. Kalli, K.R., Bartow, T.J., Hsu, P., Klickstein, L.B., Ahearn, J.M., Matsumoto, A., Fearon, D.T., 1991. Mapping of the C3b-binding site of CR1 and construction of a chimeric complement inhibitor. Complement Inflamm. 8, 171.
56. Kehrli, M.E., Schmalstieg, F.C., Anderson, D.C., van der Marten, M.J., Hughes, B.J. et al., 1990. Molecular definition of the bovine granulocythopathy syndrome: Identification of deficiency of the Mac-1 (CD11b/CD18) glycoprotein. Am. J. Vet. Res. 51, 1826-1836.
57. Kemp, R.E., Dieperink, P., Leth, P., Jesenius, J.C., Nielsen, B., Lillevang, S.T., Salomon, S., Steinbruchel, D., Larsen, S., Koch, C., White, D., 1994. Monoclonal antibodies to complement C3 prolong survival of discordant xenografts: guinea pig heart to rat transplantation. Transplant. Proc. 26, 1011-1015.
58. Kirschfink, M., 1997. The clinical laboratory: Testing the complement system. In: Rother, K., Hänsch, G.M., Till, G. (Eds.), The Complement System. Springer, Heidelberg/New York, in press.
59. Kirschfink, M., Kovacs, B., Mottaghy, K., 1993. Extracorporeal circulation: In vivo and in vitro analysis of complement activation by heparin-bonded surfaces. Circ. Shock 40, 221-226.
60. Kirschfink, M., Wienert, T., Rother, K., Pomer, S., 1992. Complement activation in renal allograft recipients. Transpl. Proc. 24, 2556-2557.
61. Kaneko, Y., Okada, N., Baranyi, L., Azuma, T., Okada, H., 1995. Antagonistic peptides against human anaphylatoxin C5a. Immunology 86, 149-154.
62. Kobayashi, T., Neethling, F.A., Koren, E., Taniguchi, S., Ye, Y., Niekrasz, M., Takagi, H., Hancock, W.W., Cooper, D.K., 1996. In vitro and in vivo investigation of anticomplement agents FUT-175 and K76COOH, in the prevention of hyperacute rejection following discordant xenotransplantation in a nonhuman primate model. Transplant. Proc. 28, 604.
63. Kola, A., Baensch, M., Bautsch, W., Hennecke, M., Klos, A., Casaretto, M., Köhl, J., 1996. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and side-directed mutagenesis. Immunotechnology 2, 115-126.
64. Kooyman, D.L., Byrne, G.W., McClellan, S., Nielsen, D., Tone, M., Waldmann, H., Coffman, T.M., McCurry, K.R., Platt, J.L., Logan, J.S., 1995. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 269, 89-92.
65. Kroshus, T.J., Bolman, R.M. III, Dalmasso, A.P., Rollins, S.A., Guilmette, E.R., Williams, B.L., Squinto, S.P., Fodor, W.L., 1996. Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 61, 1513-1521.
66. Kroshus, T.J., Rollins, S.A., Dalmasso, A.P., Elliott, E.A., Matis, L.A., Squinto, S.P., Bolman, R.M., 1995. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 60, 1194-1202.
67. Langford, G.A., Yannoutsos, N., Cozzi, E., Lancaster, R., Elsome, K., Chen, P., Richards, A., White, D.J.G., 1994. Production of pigs transgenic for human decay accelerating factor. Transplant. Proc. 26, 1400-1401.
68. Lanza, T.J., Durette, P.L., Rollins, T., Siciliano, S., Cianciarulo, D.N., Kobayashi, S.V., Caldwell, C.G., Springer, M.S., Hagmann, W.K., 1992. Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding. J. Med. Chem. 35, 252-258.
69. Lutz, H.U., Stammler, P., Jelezarova, E., Nater, M., Späth, P.J., 1996. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 88, 184-193.
70. Magee, J.C., Collins, B.H., Harland, R.C., Lindman, B.J., Bollinger, R.R., Frank, M.M., Platt, J.L., 1995. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J. Clin. Invest. 96, 2404-2412.
71. Mathieson, P.W., Qasim, F.J., Thiru, S., Oldroyd, R.G., Oliveira, D.B., 1994. Effects of decomplementation with cobra venom factor on experimental vasculitis. Clin. Exp. Immunol. 97, 474-477.
72. Miletic, V.D., Hester, C.G., Frank, M.M., 1996. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J. Immunol. 156, 749-757.
73. Moen, O., Høgasen, K., Fosse, E., Dregelid, E., Brockmeier, V., Heggen, G. et al., 1997. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann. Thorac. Surg., in press.
74. Mollnes, T.E., 1997. Biocompatibility: Complement as a mediator of tissue damage and an indicator of incompatibility. Clin. Exp. Immunogenet. 14, 24-29.
75. Mollnes, T.E., Riesenfeld, J., Garred, P., Nordström, E., Høgasen, K., Fosse, E., Götze, O., Harboe, M., 1995. A new model for evaluation of biocompatibility: Combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif. Organs. 19, 909-917.
76. Morgan, B.P., 1990. Complement. Clinical Aspects and Relevance to Disease. Harcourt Brace Jovanovich, London/New York.
77. Morgan, E.L., Ember, J.A., Sanderson, S.D., Scholz, W., Buchner, R., Ye, R.D., Hugli, T.E., 1993. Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J. Immunol. 151, 377-380.
78. Mouthon, L., Kaveri, S.V., Spalter, S.H., Lacroix Desmazes, S., Lefranc, C., Desai, R., Kazatchkine, M.D., 1996. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 104 (Suppl. 1), 3-9.
79. Müller-Eberhard, HJ., 1988. Molecular organization and function of the complement system. Ann. Rev. Biochem. 57, 321-347.
80. Mulligan, M.S., Smith, C.W., Anderson, D.C., Todd, R.F., Miyasaka, M., Tamatani, T., Issekutz, T.B., Ward, P.A., 1993a. Role of leukocyte adhesion molecules in complement-induced injury. J. Immunol. 150, 2401-2406.
81. Mulligan, M.S., Wilson, G.P., Todd, R.F., Smith, C.W., Anderson, D.C., Varani, J., Issekutz, T.B., Miyasaka, M., Tamatani, T., Rusche, J.R., Vaporciyan, A.A., Ward, P.A., 1993b. Role of β1 and β2 integrins and ICAM-1 in lung injury following deposition of IgG and IgA immune complexes. J. Immunol. 150, 2407-2417.
82. Mulligan, M.S., Schmid, E., Till, G.O., Hugli, T.E., Friedl, H.P., Roth, R.A., Ward, P.A., 1997. C5a-dependent up-regulation in vivo of lung vascular P-selectin. J. Immunol. 158, 1857-1861.
83. Newburger, J.W., Takahashi, M., Burns, J.C., Beiser, A.S., Chung, K.J., Duffy, C.E. et al., 1986. The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 315, 341-347.
84. Nürnberger, W., Göbel, U., 1996. Capillary leak syndrome following bone marrow transplantation. Biomed. Progr. 9, 8-11.
85. Nuijens, J.H., Huijbregts, C.C., Eerenberg-Belmer, A.J., Abbink, J.J., Strak van Schijndel, R.J., Felt-Bersma, R.J., Thijs, L.G., Hack, C.E., 1988. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein - C1-inhibitor complexes in sepsis. Blood 72, 1841-1848.
86. 2-terminal domain. J. Immunol. 151, 3785-3794.
87. Piddlesden, S.J., Storch, M.K., Hibbs, M., Freeman, A.M., Lassmann, H., Morgan, B.P., 1994. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152, 5477-5484.
88. Platt, J.L., Bach, F.H., 1991. The barrier to xenotransplantation. Transplantation 52, 937-947.
89. Pruitt, S.K., Bollinger, R.R., 1991. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J. Surg. Res. 50, 350-355.
90. Rabenovici, R., Yeh, C.G., Hillegass, L.M., Griswold, D.E., DiMartino, M.J., Vernick, J., Fong, K.L.L., Feuerstein, G., 1992. Role of complement in endotoxin/platelet-activating factor-induced lung injury. J. Immunol. 149, 1744-1750.
91. Radke, A., Mottaghy, K., Goldmann, Ch., Eisele, B., Hettich, R., Kirschfink, M., 1995. The protective effect of C1-inhibitor on thermal trauma: First results from an animal study. In: Roussos C. (Ed.), 8th European Congress of Intensive Care Medicine. Mundozzi Editore, Bologna, pp. 761-769.
92. Redmond, J.M., Gillinov, M.A., Stuart, R.S., Zehr, K.J., Winkelstein, J.A., Herskowitz, A. et al., 1993. Heparin-coated bypass circuits reduce pulmonary injury. Ann. Thorac. Surg. 56, 474-479.
93. Ren, X.D., Huang, S.J., Sun, J.J., Zhu, Z.G., 1994. Protective effect of cobra venom factor on pulmonary injury induced by oleic acid. Int. J. Immunopharmacol. 16, 969-975.
94. Rollins, S.A., Matis, L.A., Springhorn, J.P., Setter, E., Wolff, D.W., 1995. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 60, 1284-1292.
95. Rollins, S.A., Rinder, H.M., Rinder, C.S., Fitch, J.C.K., Smith, B.R., Mines, R.L., Alford, B.L., Matis, L.A., 1997. A humanized anti-C5 scFv blocks platelet and leukocyte activation and exhibits prolonged pharmacokinetics and pharmacodynamics in humans. Exp. Clin. Immunogenet. 14, 36.
96. Rother, K., Till, G.D., 1988. The Complement System. Springer, Berlin/Heidelberg/New York.
97. Rother, K., Rother, U., 1986. Hereditary and acquired complement deficiencies in animals and man. Progress in Allergy, vol. 39. Karger, Basel/London/New York.
98. Sadahiro, M., McDonald, T.O., Allen, M.D., 1993. Reduction in cellular and vascular rejection by blocking leukocyte adhesion molecule receptors. Am. J. Pathol. 142, 675-683.
99. Schapira, M., Agostoni de, A., Schifferli, J.A., Colman, R.W., 1985. Biochemistry and pathophysiology of human C1 inhibitor: Current issues. Complement 2, 111-126.
100. Schmoeckel, M., Nollert, G., Shahmohammadi, M., Young, V.K., Knig, W., White, D.J., Hammer, C., Reichart, B., 1996. Human decay accelerating factor successfully protects pig hearts from hyperacute rejection by human blood. Transplant. Proc. 28, 768-769.
101. Simpson, P.J., Todd, R.F. III, Fantone, J.C., Mickelson, J.K., Griffin, J.D., Lucchesi, B.R., Adams, M.D., Hoff, P., Leeh, K., Rogers, C.E., 1988. Reduction of experimental canine reperfusion injury by a monoclonal antibody (anti-Mol, anti-CD11b) that inhibits leukocyte adhesion. J. Clin. Invest. 81, 624-629.
102. Smedegard, G., Cui, L., Hugli, T.E., 1989. Endotoxin-induced shock in the rat. A role for C5a. Am. J. Pathol. 135, 489-497.
103. Stevens, J.H., O'Hanley, P., Shapiro, J.M., Mihm, F.G., Satoh, P.S., Collins, J.A., Raffin, T.A., 1986. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77, 1812-1816.
104. Stieh, J., Harding, P., Scheewe, J., Dütschke, P., Kramer, H.H., 1996. Capillary leak syndrome after open heart surgery for congenital heart defects: Therapy with C1-inhibitor. Biomed. Progr. 9, 13-16.
105. Stiehm, E.R., Ashida, E., Kim, K.S., Winston, D.J., Haas, A., Gale, R.P., 1987. Intravenous immunoglobulins as therapeutic agents (clinical conference). Ann. Int. Med. 107, 367-382.
106. Stöve, S., Welte, T., Wagner, T.O.F., Kola, A., Klos, A., Bautsch, W., Köhl, J., 1996. Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin. Diagn. Lab. Immunol. 3, 175-183.
107. Storck, M., Abendroth, D., Prestel, R., Pino-Chavez, G., Müller-Höker, J., White, D.J.G., Hammer, C., 1997. Morphology of hDAF (CD55) transgenic pig kidneys following ex-vivo hemoperfusion with human blood. Transplantation 63, 304-310.
108. Thomas, H., Maillet, F., Letourneur, D., Jozefonvicz, J., Kazatchkine, M.D., 1995. Effect of substituted dextran derivative on complement activation in vivo. Biomaterials 16, 1163-1167.
109. Thomas, H., Maillet, F., Letourneur, D., Jozefonvicz, J., Fischer, E., Kazatchkine, M.D., 1996. Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. Mol. Immunol. 33, 643-648.
110. Turner, M.W., 1996. Mannose-binding lectin: The pluripotent molecule of the innate immune system. Immunol. Today 17, 532-540.
111. Vriesendorp, F.J., Flynn, R.E., Pappolla, M.A., Koski, C.L., 1995. Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J. Neuroimmunol. 58, 157-165.
112. Wang, Y., Hu, Q., Madri, J.A., Rollins, S.A., Chodera, A., Matis, L.A., 1996. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA 93, 8563-8568.
113. Wang, Y., Rollins, S.A., Madri, J.A., Matis, L.A., 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92, 8955-8959.
114. Weisman, H.F., Bartow, T., Leppo, M.K., Marsh, H.C. Jr., Carson, G.R., Concino, M.F., Boyle, M.F., Roux, K.H., Weisfeldt, M.L., Fearon, D.T., 1990. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249, 146-151.
115. Würzner, R., Schulze, M., Happe, L., Franzke, A., Bieber, F.A., Opermann, M., Götze, O., 1991. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm. 8, 328-340.
116. Yanamoto, H., Kikuchi, H., Sato, M., Shimizu, Y., Yoneda, S., Okamoto, S., 1992. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery 30, 358-363.
117. Yeh, C.G., Marsh, H.C. Jr., Carson, G.R., Berman, L., Concino, M.F., Scesney, S.M., Kuestner, R.E., Skibbens, R., Donahue, K.A., Ip, S.H., 1991. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive Arthus reaction in rats. J. Immunol. 146, 250-256.
118. Zilow, G., Sturm, J.A., Rother, U., Kirschfink, M., 1990. Complement activation and the prognostic value of C3a in patients at risk of the adult respiratory distress syndrome. Clin. Exp. Immunol. 79, 151-157.